Overview
BVS market data
Price History
No market bars yet for BVS. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for BVS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare ConferenceGlobenewswire Inc · Jun 2, 2026, 11:15 AM
Transcript: Bioventus Q1 2026 Earnings Conference CallBenzinga · Jun 1, 2026, 10:46 AM
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItBenzinga · May 22, 2026, 3:15 PM
Bioventus Says FDA Reclassifies Exogen Ultrasound Bone Healing System To Class II Device On April 16, 2026; CMS Updates Medicare Fee Schedule For Non-Invasive Bone Growth Stimulators Effective May 18, 2026; Does Not Expect Material Impact From Exogen Reimbursement Changes In FY26; Reiterates 2026 Financial Guidance - SEC FilingBenzinga · May 21, 2026, 9:25 PM
8-K filing — Bioventus Inc. (BVS)SEC EDGAR · May 21, 2026, 8:58 PM